Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - Chemomab Therapeutics Ltd. | tm2029629d1_ex32-1.htm |
| EX-31.2 - EXHIBIT 31.2 - Chemomab Therapeutics Ltd. | tm2029629d1_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - Chemomab Therapeutics Ltd. | tm2029629d1_ex31-1.htm |
| 10-Q - FORM 10-Q - Chemomab Therapeutics Ltd. | tm2029629d1_10q.htm |
Exhibit 32.2
Certification Of
Principal Financial Officer
Pursuant To 18 U.S.C. Section 1350,
As Adopted Pursuant To
Section 906 Of The Sarbanes-Oxley Act Of 2002
In connection with the Quarterly Report of Anchiano Therapeutics, Ltd. (the “Company”) on Form 10-Q for the period ended September 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Andrew Fine, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
| 1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| 2) | The information contained in the Report fairly presents, in all material respects, the financial condition of the Company at the end of the period covered by the Report and results of operations of the Company for the period covered by the Report. |
| Dated: November 16, 2020 | /s/ Andrew Fine |
| Andrew Fine | |
| Chief Financial Officer | |
| (Principal Financial Officer and Principal Accounting Officer) |